These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1048 related items for PubMed ID: 26250606

  • 1. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H, Kim Y, Sul JW, Jeong IG, Yi HJ, Ahn JB, Kang JS, Yun J, Hwang JJ, Kim CS.
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 3. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T, Sun Q, Li Q, Yang H, Zhang Y, Wang R, Lin X, Xiao D, Yuan Y, Chen L, Wang W.
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
    Zhou S, Dai Z, Wang L, Gao X, Yang L, Wang Z, Wang Q, Liu Z.
    J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
    Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, Selfe JL, Thway K, Pietsch T, Pearson AD, Shipley J.
    Clin Cancer Res; 2013 Nov 01; 19(21):5940-51. PubMed ID: 23918606
    [Abstract] [Full Text] [Related]

  • 8. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y, Chen X, Luo Z.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun 01; 30(6):592-6. PubMed ID: 24909280
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.
    PLoS One; 2012 Jun 01; 7(7):e40439. PubMed ID: 22808163
    [Abstract] [Full Text] [Related]

  • 11. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K.
    Med Sci Monit; 2018 May 08; 24():3002-3010. PubMed ID: 29737325
    [Abstract] [Full Text] [Related]

  • 12. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    Neoplasia; 2014 Jan 08; 16(1):43-72. PubMed ID: 24563619
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
    Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR.
    Br J Cancer; 2012 Apr 10; 106(8):1386-94. PubMed ID: 22415236
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.
    Cancer Biol Ther; 2011 Jun 01; 11(11):938-46. PubMed ID: 21464613
    [Abstract] [Full Text] [Related]

  • 17. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 18. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 19. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H, Kosaka T, Oya M.
    Cancer Sci; 2018 Sep 31; 109(9):2937-2945. PubMed ID: 29989268
    [Abstract] [Full Text] [Related]

  • 20. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
    Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.
    Clin Cancer Res; 2010 Dec 15; 16(24):6029-39. PubMed ID: 21169255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.